tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ADMA Biologics boosts FY23 revenue view to exceed $250M from $240M previously

ADMA now anticipates FY 2023 total revenues to exceed $250M increased from $240M previously. Further, ADMA anticipates continued growth in Net Income and Adjusted EBITDA over the remainder of 2023. Consensus for FY23 revenue $243.06M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ADMA:

Disclaimer & DisclosureReport an Issue

1